BUILDING SAFER AND MORE POTENT TREATMENTS
OUR SOLUTION
Deliver safer and more potent ADCs Targeting Surface Protein Complexes
DISCOVERY
As reported by Centrose in Nature Communications, a cell’s Surfaceome is a collection of distinct interacting proteins that allow the cell to function and communicate with other cell types. Importantly, these networks are cell type specific and thus can be targeted with precision medicines.
EDCs are True Next-Gen ADCs
EDCs are antibody drug conjugates (ADCs) that don’t require internalization, nor do they require breakdown. In fact, for EDCs to work, the drug has to be attached to the antibody and the two target proteins have to be outside of the cell. This is why we named them Extracellular Drug Conjugates or EDCs, a true Next-Gen ADC platform.
Benefits of Extracellular Targeting
Centrose was the first to show that that a new type of ADC could selectively kill cancer cells by directing a potent small molecule drug to a community of proteins found only on the surface of metastatic cancer cells. When the EDC was added to these cells in vitro or in vivo, the growing cancer could be specifically destroyed, leaving all other cells untouched. Centrose went on to discover that other protein communities could also be selectively targeted. More recent studies show that in non-human primates, specific blood types can also be selectively removed using EDC Technology.
As we reported in cell press publication, Centrose provides data showing that proteins like CD20 and CD38 also are involved in cell surface communities. With this knowledge, Centrose has since developed a number of EDCs for different cancer types like lung, pancreatic and lymphomas.
PIPELINE
EDC9 targets drug resistant NHL.
EDC1 targets metastatic cancers.
EDC8 targets certain types of lymphoma.
